Latest Trastuzumab Stories

Cancer researchers at Georgetown University's Lombardi Comprehensive Cancer Center have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma tumors in cell and animal studies. Glioblastoma is the deadliest of brain cancers; there is no effective treatment.In the current online issue of the journal Oncogene, the researchers demonstrate how this antibody latches onto a receptor that studs the outside of glioblastoma cells, preventing a growth factor...

Study in mice holds potential for people diagnosed with cancer, according to studyA new study published in the July issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET) scans in mice can be used to determine whether a novel type of breast cancer treatment is working as intended. Researchers successfully used PET and a specially-developed radioactive compound to image HER2"”a protein often associated with aggressive breast cancer"”in breast cancer cells...

PARIS and BRISBANE, California, June 3 /PRNewswire-FirstCall/ -- - Data Highlighted in Plenary Session of 2009 American Society of Clinical Oncology Annual Meeting Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial of BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, in combination with gemcitabine and carboplatin (GC) chemotherapy, in patients with metastatic...

Gene overexpressed in up to 20 percent of breast cancers responds to blood pressure drug in lab, U-M researchers report Researchers have identified a gene that is overexpressed in up to 20 percent of breast cancers and that could be blocked in the lab by a currently available blood pressure drug, according to a new study from the University of Michigan Comprehensive Cancer Center.The gene, called AGTR1, caused normal breast cells to behave like cancer cells. This behavior was reversed by...

COLLEGEVILLE, Pa., May 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab (Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) breast cancer, and a separate study investigating neratinib safety and efficacy when given with paclitaxel (Taxol(R), Bristol-Myers Squibb) in patients with HER-2 dependent solid tumors. The data...

A new study finds that nearly one in four African American women with late stage breast cancer refused chemotherapy and radiation therapy, potentially life saving therapies. Published in the July 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that more efforts are needed to ensure that all women with breast cancer receive appropriate care.In the United States, African American women have almost twice the rate of advanced (stage III) breast...

ORLANDO, Fla., May 18 /PRNewswire-USNewswire/ -- Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options. At the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), researchers from the Mayo Clinic campus in Florida report that using a combination of capecitabine, vinorelbine, and trastuzumab offers a treatment option that is at least as...

An oral medication could help some patients with inflammatory breast cancer.Aggressive forms of inflammatory breast cancer can be difficult to treat, often unresponsive to chemotherapy, radiation or approved medications. For patients whose disease is resistant to anthracycline or taxane and trastuzumab treatment, options are limited. However, a new study of the oral growth inhibitor, lapatinib, showed promise for patients for which all other treatment options have failed.Patients were given...

Regardless of age or body weight, black women have a threefold greater risk of developing a particularly aggressive type of breast cancer, compared with non-black women, Boston-based researchers report.This type of breast cancer is more deadly because it does not posses receptors for the hormones estrogen and progesterone, nor a protein called HER2.  This means that women with these "triple-negative tumors" cannot be helped by drugs that target estrogen and progesterone or by...

LONDON and PHILADELPHIA, April 1, /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced the submission of two simultaneous regulatory applications to expand the use of TYVERB(R)/TYKERB(R) (lapatinib). If approved, TYVERB(R)/TYKERB(R) could be used as a first-line therapy regimen combined with anti-hormonal therapy for patients with hormone-sensitive, metastatic (or advanced) breast cancer in Europe and the United States. The variation to the EU marketing authorization and...